Switch theme
Sign up to access all valuation multiples
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
1999
713
LTM Revenue $189M
LTM EBITDA $13.2M
$608M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Valneva has a last 12-month revenue of $189M and a last 12-month EBITDA of $13.2M.
In the most recent fiscal year, Valneva achieved revenue of $182M and an EBITDA of $34.5M.
Valneva expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Valneva valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $165M | $182M | XXX | XXX | XXX |
| Gross Profit | $39.6M | $56.8M | XXX | XXX | XXX |
| Gross Margin | 24% | 31% | XXX | XXX | XXX |
| EBITDA | -$62.0M | $34.5M | XXX | XXX | XXX |
| EBITDA Margin | -38% | 19% | XXX | XXX | XXX |
| Net Profit | -$154M | -$109M | XXX | XXX | XXX |
| Net Margin | -93% | -60% | XXX | XXX | XXX |
| Net Debt | n/a | $54.5M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Valneva's stock price is EUR 3 (or $3).
Valneva has current market cap of EUR 518M (or $557M), and EV of EUR 566M (or $608M).
See Valneva trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $608M | $557M | XXX | XXX | XXX | XXX | $-0.22 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Valneva has market cap of $557M and EV of $608M.
Valneva's trades at 3.2x LTM EV/Revenue multiple, and 46.0x LTM EBITDA.
Analysts estimate Valneva's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Valneva and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $608M | XXX | XXX | XXX |
| EV/Revenue | 3.3x | XXX | XXX | XXX |
| EV/EBITDA | 17.7x | XXX | XXX | XXX |
| P/E | -42.3x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -6.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpValneva's NTM/LTM revenue growth is 18%
Valneva's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Over next 12 months, Valneva's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Valneva's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Valneva and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -156% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 37% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 31% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 25% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 44% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 88% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| CSL | XXX | XXX | XXX | XXX | XXX | XXX |
| Imugene | XXX | XXX | XXX | XXX | XXX | XXX |
| Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Valneva acquired XXX companies to date.
Last acquisition by Valneva was XXXXXXXX, XXXXX XXXXX XXXXXX . Valneva acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Valneva founded? | Valneva was founded in 1999. |
| Where is Valneva headquartered? | Valneva is headquartered in France. |
| How many employees does Valneva have? | As of today, Valneva has 713 employees. |
| Who is the CEO of Valneva? | Valneva's CEO is Mr. Thomas Lingelbach. |
| Is Valneva publicy listed? | Yes, Valneva is a public company listed on PAR. |
| What is the stock symbol of Valneva? | Valneva trades under VLA ticker. |
| When did Valneva go public? | Valneva went public in 2007. |
| Who are competitors of Valneva? | Similar companies to Valneva include e.g. CSL, Imugene, Prescient Therapeutics, GSK India. |
| What is the current market cap of Valneva? | Valneva's current market cap is $557M |
| What is the current revenue of Valneva? | Valneva's last 12-month revenue is $189M. |
| What is the current EBITDA of Valneva? | Valneva's last 12-month EBITDA is $13.2M. |
| What is the current EV/Revenue multiple of Valneva? | Current revenue multiple of Valneva is 3.2x. |
| What is the current EV/EBITDA multiple of Valneva? | Current EBITDA multiple of Valneva is 46.0x. |
| What is the current revenue growth of Valneva? | Valneva revenue growth between 2023 and 2024 was 10%. |
| Is Valneva profitable? | Yes, Valneva is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
